GlassScriptPhysician profile
Michelle Kaplan
NPI 1336263169
$9,614.34
in general payments reported to CMS, 2019-2025
21 companies · $41.66 in 2025
The $41.66 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $761 · 2021: $1,858 · 2022: $1,083 · 2023: $4,788 · 2024: $699 · 2025: $41.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Food and Beverage: $2,016 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Food and Beverage | $2,016.39 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,918.66 | 2021-2024 | |
| Alkermes, INC. | $649.34 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $620.33 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $609.45 | 2019-2024 | Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $534.47 | 2020-2024 | Caplyta |
| Allergan, INC. | $515.93 | 2019-2020 | |
| Lundbeck LLC | $338.38 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $318.39 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $222.60 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $199.49 | 2019-2021 | |
| Almatica Pharma LLC | $164.37 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Avanir Pharmaceuticals, INC. | $123.52 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $90.39 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $85.75 | 2022-2024 | Ingrezza |
| Corium, LLC | $48.73 | 2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $43.80 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $37.90 | 2022-2023 | Quviviq |
| Alfasigma USA, INC. | $37.63 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.08 | 2021 | |
| Shire North American Group INC | $20.22 | 2019 | |
| Eisai INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.